Successful targeting of ErbB2 receptors—is PTEN the key?  by Crowder, Robert J. et al.
CANCER CELL : AUGUST 2004 · VOL. 6 · COPYRIGHT © 2004 CELL PRESS 103
Trastuzumab, a humanized monoclonal
antibody, is an effective treatment for
advanced breast cancer with ErbB2
gene amplification. While not a cure for
disseminated disease, major tumor
regressions are often seen, particular in
combination with chemotherapy. Despite
careful patient selection on the basis of
ErbB2 fluorescence in situ hybridization,
only a minority of patients respond to
trastuzumab monotherapy. Furthermore,
trastuzumab has not shown as much effi-
cacy against other ErbB2-expressing
malignancies such as lung and pancreas
cancer. Overall, these observations
suggest that ErbB2 gene amplification 
is necessary but not sufficient for
trastuzumab responsiveness.
What are the other factors that deter-
mine trastuzumab efficacy? An answer
to this question could provide new pre-
dictive biomarkers, as well as strategies
to improve efficacy. Insights are limited,
mostly because it is not clear how
trastuzumab actually works.The antineo-
plastic effect might depend on engaging
Fc γ receptors on immune effector cells
through the immunoglobulin G1 Fc
region of trastuzumab (Clynes et al.,
2000). Trastuzumab may internalize the
receptor, thereby preventing plasma
membrane signaling (Sliwkowski et al.,
1999). There is also evidence that
trastuzumab decreases cleavage of
p185erbB2 ectodomain, preventing the for-
mation of a truncated yet highly active
receptor remnant (Molina et al., 2001).
There have been few attempts to docu-
ment the relative contributions of these
mechanisms in human studies, because
study designs demand solutions to
the technically challenging problems of
accurately monitoring trastuzumab-
dependent immune effects, receptor
modifications, and changes in the cellu-
lar location of ErbB2.
Work with small-molecule ErbB2 tyro-
sine kinase inhibitors are not complicated
by concerns over the contributions of the
immune system or complex antibody-
mediated receptor effects. Therefore,
translational studies have focused on the
ability of these alternative ErbB2 targeting
agents to disrupt signal transduction.
Interestingly, posttreatment biopsies from
patients treated with the ErbB2 inhibitor
GW572016 often show successful inhibi-
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Successful targeting of ErbB2 receptors—is PTEN the key?
Women with ErbB2-positive breast cancer have a poor prognosis, and frequently, chemotherapy treatment is ineffective.
The ErbB2-targeted antibody trastuzumab improves survival when given with chemotherapy to patients with ErbB2-over-
expressing metastatic disease, but treatment is not curative, and primary resistance is common. Postulated mechanisms
of action for trastuzumab include immune-mediated cytotoxicity and receptor downmodulation. A study in this issue of
Cancer Cell suggests that trastuzumab causes rapid activation of the PTEN lipid phosphatase, which in turn downregu-
lates the phosphatidylinositol 3′-kinase (PI3K) pathway. Resistance to trastuzumab occurs when PTEN function is lost,
suggesting that PTEN activation is a critical component of the therapeutic effect.
Figure 1. Inhibition of ErbB2/PI3K signaling by
trastuzumab
Top: overexpression of ErbB2 results in the for-
mation of homodimers with autophosphory-
lation of tyrosine residues within the
intracellular domain. These phosphorylated
tyrosine residues of ErbB2 serve to recruit
intracellular signaling molecules, including
the non-receptor tyrosine kinase Src and
components of phosphatidylinositol 3-kinase
(PI3K catalytic subunit and p85 adaptor), to
the intracellular domain of ErbB2. Activated
PI3K generates 3-phosphorylated phospho-
inositide products (PIP3) that directly or
indirectly (solid arrows) (through the phos-
phoinoside-dependent protein kinases
[PDK]) lead to the activation of downstream
targets of PI3K, including the serine-threonine
protein kinase Akt. Upon phosphorylation, Src
becomes activated and phosphorylates the
tumor suppressor PTEN on tyrosine residues
within the PTEN C2 domain, preventing PTEN
from translocating to the plasma membrane
and dephosphorylating PI3K-generated PIP3.
These signaling mechanisms lead to the sus-
tained activation of the PI3K signaling path-
way and promote PI3K-regulated cellular processes, including cell proliferation, survival, and protein synthesis. Left top arrow and lower left figure:
treatment with trastuzumab results in a rapid downregulation of PI3K signaling. Within minutes of trastuzumab treatment, Src becomes displaced
from ErbB2, leading to the dephosphoryation and inactivation of Src. PTEN, no longer held in an inactive state by Src phosphorylation, translocates
to the plasma membrane and dephosphorylates PIP3, thereby decreasing the activity of PI3K downstream targets (dashed arrows), including Akt,
which is inactivated following dephosphorylation. Top right arrow and lower right figure: in an alternative model, long-term trastuzumab treatment
(>20 hr) may result in the internalization of ErbB2, thereby removing ErbB2 from the plasma membrane and preventing its signaling functions. ErbB2
becomes dephosphorylated and degraded upon internalization. Both short- and long-term processes mediated by trastuzumab inhibit cellular
functions promoted by activated ErbB2. The relative contribution of these two potential inhibitory effects to the efficacy of trastuzumab remains
unclear, but both would be attenuated by the presence of constitutive activation of the PI3K pathway.
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tion of receptor autophosphorylation 
in the absence of the anticipated fall in
tumor cell cycle markers and increase in
apoptosis (Burris et al., 2003). This sug-
gests that key growth and survival path-
ways remain active despite successful
ErbB2 inhibition. A number of investiga-
tors have recently implicated the phos-
phatidylinositol 3′-kinase (PI3K) pathway
in small-molecule ErbB1 inhibitor resis-
tance (Bianco et al., 2003; She et al.,
2003). Constitutive PI3K signaling from
loss of expression from the PTEN tumor
suppressor gene (Eng, 2003) or gain-of-
function mutations in PIK3CA (Samuels
et al., 2004) are common enough in solid
tumors to play a major role in modulating
the efficacy of ErbB-directed signal trans-
duction therapy.
The study by Nagata et al. in this
issue of Cancer Cell (Nagata et al., 2004)
is intriguing because it suggests that the
efficacy of trastuzumab is similarly
dependent on the ability to inhibit PI3K
signaling. They report that trastuzumab
specifically downregulates PI3K signal-
ing though activation of PTEN, a powerful
lipid phosphatase. When present in the
plasma membrane, PTEN dephosphory-
lates the lipid products of PI3K and pre-
vents activation of key PI3K targets.
PTEN binds to the plasma membrane via
the C2 domain that is negatively regulat-
ed by Src-dependent tyrosine phosphor-
ylation. Trastuzumab binding rapidly
decouples Src from ErbB2 receptor. The
consequent loss of Src activity reduces
PTEN C2 domain phosphorylation and
allows PTEN to translocate to the plasma
membrane and inhibit the PI3K pathway
(Figure 1). How trastuzumab achieves
this remarkable trick was not explored in
the paper, but is likely to be a highly spe-
cific because very few ErbB targeting
antibodies have an antiproliferative effect.
Trastuzumab binds to the juxtamembrane
region of the ErbB2 ectodomain (Cho et
al., 2003), a region believed to be impor-
tant for dimerization and transmembrane
signaling. Binding of trastuzumab to
ErbB2 could therefore result in a confor-
mational change in the intracellular
domain of ErbB2 that obscures the Src
binding site. Alternatively, trastuzumab
may induce perturbations in membrane
domains, such as lipid rafts, that alter Src
binding or Src access to phosphorylated
ErbB2. Another area of future research
would be an examination of the effect of
trastuzumab on the interactions between
ErbB2 and the plethora of other second
messengers that dock with the receptor
in its activated state, as the effect of
trastuzumab on Src binding may not be
selective.
If activation of PTEN is the key to the
therapeutic action of trastuzumab, then
cancer cells that have lost PTEN should
show resistance to treatment. In this
paper, animal modeling supports this
postulate, since an antisense-mediated
reduction in tumor PTEN inhibited the
efficacy of trastuzumab monotherapy. As
expected, the antisense effect was
reversed with a pharmacological inhibitor
of PI3K. This was not only a good control
for the antisense experiment, but the
result also carries the message that the
efficacy of trastuzumab could be
enhanced with inhibitors of the PI3K
pathway. Finally, the investigators looked
to patient material to correlate PTEN
expression (by immunohistochemistry
techniques in archived tumor speci-
mens) and the effectiveness of combina-
tion treatment with paclitaxel and
trastuzumab. It would have been more
satisfying to conduct these experiments
in the context of trastuzumab monother-
apy, since despite their attempts to deal
with the issue, PTEN status could still
influence paclitaxel efficacy complicating
the interpretation of their results. In addi-
tion, some PTEN expression subgroups
had only a few patients, making firm con-
clusions difficult to draw because of
small sample sizes. Moreover, PTEN
expression may resemble a continuous
biological variable, so retrospectively
redefining expression in terms of PTEN
“negative” or “positive” is difficult and 
has to be interpreted cautiously.
Nonetheless, it is fair to conclude that the
investigators secured enough prelimi-
nary data to pursue the hypothesis fur-
ther. Currently, thousands of patients are
undergoing treatment on trastuzumab
adjuvant trials. Formalin-fixed tumor
samples should be readily available to
test whether trastuzumab resistance is
associated with loss of PTEN expres-
sion. Their data suggest it might also be
worthwhile reconsidering trastuzumab-
based chemotherapy for other ErbB2-
expressing malignancies if the principle
reason for failure were inadequate PI3K
inhibition that could be overcome with
the addition of a PI3K pathway inhibitor.
The overall allure of this paper is the
suggestion that the rigorous pursuit of
the status of critical signaling molecules
in the tumors we target for trastuzumab
and ErbB2 small molecule inhibitors
should be a key aspect of our clinical
approach to ErbB2-positive breast can-
cer. Adequate technical approaches for
high-throughput biomarker analysis of
formalin-fixed tissue by quantitative
RTPCR, gene sequencing, and tissue
microarray are now at hand and should
be applied in a rigorous manner. For opti-
mal success, matching individual tumor
signaling anomalies with a customized
treatment strategy will ultimately provide
the most effective way to take advantage
of the ever-increasing list of new biologi-
cal therapies for cancer.
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